151. Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network.
- Author
-
Andrew MK, Pott H, Staadegaard L, Paget J, Chaves SS, Ortiz JR, McCauley J, Bresee J, Nunes MC, Baumeister E, Raboni SM, Giamberardino HIG, McNeil SA, Gomez D, Zhang T, Vanhems P, Koul PA, Coulibaly D, Otieno NA, Dbaibo G, Almeida MLG, Laguna-Torres VA, Drăgănescu AC, Burtseva E, Sominina A, Danilenko D, Medić S, Diez-Domingo J, and Lina B
- Abstract
Background: The Global Influenza Hospital Surveillance Network (GIHSN) was established in 2012 to conduct coordinated worldwide influenza surveillance. In this study, we describe underlying comorbidities, symptoms, and outcomes in patients hospitalized with influenza., Methods: Between November 2018 and October 2019, GIHSN included 19 sites in 18 countries using a standardized surveillance protocol. Influenza infection was laboratory-confirmed with reverse-transcription polymerase chain reaction. A multivariate logistic regression model was utilized to analyze the extent to which various risk factors predict severe outcomes., Results: Of 16 022 enrolled patients, 21.9% had laboratory-confirmed influenza; 49.2% of influenza cases were A/H1N1pdm09. Fever and cough were the most common symptoms, although they decreased with age ( P < .001). Shortness of breath was uncommon among those <50 years but increased with age ( P < .001). Middle and older age and history of underlying diabetes or chronic obstructive pulmonary disease were associated with increased odds of death and intensive care unit (ICU) admission, and male sex and influenza vaccination were associated with lower odds. The ICU admissions and mortality occurred across the age spectrum., Conclusions: Both virus and host factors contributed to influenza burden. We identified age differences in comorbidities, presenting symptoms, and adverse clinical outcomes among those hospitalized with influenza and benefit from influenza vaccination in protecting against adverse clinical outcomes. The GIHSN provides an ongoing platform for global understanding of hospitalized influenza illness., Competing Interests: Potential conflicts of interest. MKA reports honoraria for advisory activities from Pfizer, Sanofi, and Seqirus and grant funding from Sanofi, GSK, Pfizer, Canadian Frailty Network, and Canadian Institutes of Health Research, unrelated to the current study. HP reports grant funding from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001. SSC works for Sanofi when not seconded to the Foundation for Influenza Epidemiology. GD reports research grant funding to his institution from Pfizer, Sanofi, and MSD and honoraria from Pfizer, MSD, Sanofi. MCN reports grants from the Bill & Melinda Gates Foundation, European & Developing Countries Clinical Trials Partnership, Pfizer, AstraZeneca, and Sanofi, and honoraria for advisory activities from Sanofi. JRO reports that his institution has received research grants from Pfizer and National Institutes of Health for vaccine research, and he has received honoraria for advisory activities from GSK, Moderna, Pfizer, and Seqirus, outside the submitted work. SM reports honoraria and consulting fees from Sanofi and GlaxoSmithKline. PV reports honoraria from Pfizer. JP and LS report grant funding from Sanofi Pasteur, unrelated to the current work. HIGG and SMR report conference attendance funding from Sanofi. SAM reports grant and clinical trials funding from GSK, Merck, Pfizer, and Sanofi and payments from GSK, Pfizer, Sanofi, and Merck outside the submitted work. Acd reports grant funding from the EU/EFPIA Innovative medicine Initiative 2 Joint Undertaking (DRIVE Grant Number 777363). TZ reports grants from Pfizer and MSD. BL serves as chair of the scientific committee of Immuniser Lyon and co-chair of the Global Influenza Initiative. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF